Taipei, Taiwan, December 10, 2024 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader headquartered in Taiwan, announced its unaudited consolidated revenue for November 2024, totaling NT$1,061 million. This brings the company’s year-to-date revenue to NT$17,121 million, marking a 9.9% year-over-year (YoY) growth and surpassing the total revenue for 2023.
Year-to-date, the company’s Asian revenues rose by 5% compared to the same period last year. Among all Asian markets, Thailand led the growth with over 100% YoY increase. Since incorporating Teva Pharm Thailand in August, Lotus has optimized its product line with new oncology products. This integration has driven significant growth, with double-digit revenue increases for the oncology products in Thailand. The synergy between the new products and the experienced sales team has enhanced performance and collaboration. The products introduced by Teva Pharm Thailand such as NATEAR and Inhalex Forte also showed a sustainable growth.
For the export business, year-to-date revenue increased by 16% YoY, with strong sales from lenalidomide offsetting the decline of gSuboxone this year.
Lotus has been actively expanding its footprint in Southeast Asia. Year-to-date, the company has announced two acquisitions: Teva Pharm Thailand and the anti-inflammatory product Alpha Choay in Vietnam and Cambodia with annual sales of US$22mn. Lotus completed the transaction for Teva Pharm Thailand in August and expects to close the Alpha Choay deal at the beginning of 2025, earlier than the company’s previous expectation of the first half of 2025.
About Lotus
Founded in 1966, Lotus (1795: TT) is a global pharmaceutical company focused on delivering novel and generic medicines that are safer, better, and more accessible. With a best-in-class R&D and manufacturing platform in Asia, Lotus has partnerships in key markets including the U.S., Europe, Japan, China, and Brazil. The company manages over 100 strategic projects in development and registration across Asia and the U.S., with a portfolio of more than 250 commercial products. Lotus invests in a diversified pipeline of high-barrier oncology treatments, complex generics, 505(b)2 products, and new chemical entities (NCEs), through internal R&D and licensing partnerships. Additionally, it bolsters its portfolio with biosimilars, supported by strategic alliances. Lotus's facilities are certified by top regulatory bodies, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.
Media Inquiries:
Yu-ying Yang, Associate Director, Corporate communication.
+886 2 2700 5908
investor@lotuspharm.com